192 related articles for article (PubMed ID: 37219907)
1. Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer.
Zamboglou C; Peeken JC; Janbain A; Katsahian S; Strouthos I; Ferentinos K; Farolfi A; Koerber SA; Debus J; Vogel ME; Combs SE; Vrachimis A; Morganti AG; Spohn SKB; Shelan M; Aebersold DM; Grosu AL; Ceci F; Henkenberens C; Kroeze SGC; Guckenberger M; Fanti S; Belka C; Bartenstein P; Hruby G; Scharl S; Wiegel T; Emmett L; Arnoux A; Schmidt-Hegemann NS
JAMA Netw Open; 2023 May; 6(5):e2314748. PubMed ID: 37219907
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy.
Adebahr S; Althaus A; Scharl S; Strouthos I; Farolfi A; Serani F; Lanzafame H; Trapp C; Koerber SA; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Grosu AL; Kroeze SGC; Guckenberger M; Fanti S; Hruby G; Emmett L; Belka C; Schmidt-Hegemann NS; Henkenberens C; Aebersold DM; Wiegel T; Afshar-Oromieh A; Zamboglou C; Shelan M
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):558-567. PubMed ID: 37736808
[TBL] [Abstract][Full Text] [Related]
3. PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml.
Solomonidou N; Germanou D; Strouthos I; Karagiannis E; Farolfi A; Koerber SA; Debus J; Peeken JC; Vogel ME; Vrachimis A; Spohn SKB; Shelan M; Aebersold D; Grosu AL; Ceci F; Kroeze SGC; Guckenberger M; Fanti S; Belka C; Hruby G; Scharl S; Wiegel T; Bartenstein P; Henkenberens C; Emmett L; Schmidt-Hegemann NS; Ferentinos K; Zamboglou C
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2529-2536. PubMed ID: 36905411
[TBL] [Abstract][Full Text] [Related]
4. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
[TBL] [Abstract][Full Text] [Related]
5. Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy.
Campbell SR; Tom MC; Agrawal S; Efstathiou JA; Michalski JM; Abramowitz MC; Pollack A; Spratt DE; Hearn JWD; Stephans KL; Gao T; Li J; Tendulkar RD
Eur Urol Oncol; 2022 Jun; 5(3):304-313. PubMed ID: 34016556
[TBL] [Abstract][Full Text] [Related]
6. Treatment Outcomes from
Emmett L; van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P
J Nucl Med; 2017 Dec; 58(12):1972-1976. PubMed ID: 28747524
[No Abstract] [Full Text] [Related]
7. Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy.
Zamboglou C; Strouthos I; Sahlmann J; Farolfi A; Serani F; Medici F; Cavallini L; Morganti AG; Trapp C; Koerber SA; Peeken JC; Vogel MME; Schiller K; Combs SE; Eiber M; Vrachimis A; Ferentinos K; Spohn SKB; Kirste S; Gratzke C; Ruf J; Grosu AL; Ceci F; Fendler WP; Miksch J; Kroeze S; Guckenberger M; Lanzafame H; Fanti S; Hruby G; Wiegel T; Emmett L; Schmidt-Hegemann NS; Henkenberens C
Int J Radiat Oncol Biol Phys; 2022 Aug; 113(5):1015-1024. PubMed ID: 35659629
[TBL] [Abstract][Full Text] [Related]
8. Ten-Year Outcomes of Moderately Hypofractionated Salvage Postprostatectomy Radiation Therapy and External Validation of a Contemporary Multivariable Nomogram for Biochemical Failure.
Chin S; Fatimilehin A; Walshaw R; Argarwal A; Mistry H; Elliott T; Logue J; Wylie J; Choudhury A
Int J Radiat Oncol Biol Phys; 2020 Jun; 107(2):288-296. PubMed ID: 31987961
[TBL] [Abstract][Full Text] [Related]
9. Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence.
Bianchi L; Castellucci P; Farolfi A; Droghetti M; Artigas C; Leite J; Corona P; Shagera QA; Moreira R; González C; Queiroz M; de Galiza Barbosa F; Schiavina R; Deandreis D; Fanti S; Ceci F
Eur Urol Oncol; 2023 Feb; 6(1):41-48. PubMed ID: 34933814
[TBL] [Abstract][Full Text] [Related]
10. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
11. 3-Year Freedom from Progression After
Emmett L; Tang R; Nandurkar R; Hruby G; Roach P; Watts JA; Cusick T; Kneebone A; Ho B; Chan L; van Leeuwen PJ; Scheltema MJ; Nguyen A; Yin C; Scott A; Tang C; McCarthy M; Fullard K; Roberts M; Francis R; Stricker P
J Nucl Med; 2020 Jun; 61(6):866-872. PubMed ID: 31676727
[No Abstract] [Full Text] [Related]
12. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C
BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700
[TBL] [Abstract][Full Text] [Related]
13. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.
Xiang M; Ma TM; Savjani R; Pollom EL; Karnes RJ; Grogan T; Wong JK; Motterle G; Tosoian JJ; Trock BJ; Klein EA; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Levin-Epstein R; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Huland H; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Alam R; Schwen Z; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Chong N; Kupelian PA; Rettig MB; Zaorsky NG; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Tilki D; Czernin J; Gafita A; Romero T; Calais J; Kishan AU
JAMA Netw Open; 2021 Dec; 4(12):e2138550. PubMed ID: 34902034
[TBL] [Abstract][Full Text] [Related]
14. Failure Patterns by PSMA PET for Recurrent Prostate Cancer after Prostatectomy and Salvage Radiation.
Imber BS; O'Dwyer E; Lobaugh S; McBride SM; Hopkins M; Kollmeier M; Gorovets D; Brennan V; Pike LRG; Gewanter R; Mychalczak B; Zhang Z; Schöder H; Zelefsky MJ
Urology; 2022 Dec; 170():146-153. PubMed ID: 36115426
[TBL] [Abstract][Full Text] [Related]
15. Changes in Management After
Ng M; Guerrieri M; Wong LM; Taubman K; Sutherland T; Benson A; Byrne G; Koschel S; Yap K; Starmans M; Ong G; Macleod C; Foo M; Chao M
J Nucl Med; 2022 Sep; 63(9):1343-1348. PubMed ID: 35058320
[TBL] [Abstract][Full Text] [Related]
16. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
Roberts MJ; Chatfield MD; Hruby G; Nandurkar R; Roach P; Watts JA; Cusick T; Kneebone A; Eade T; Ho B; Nguyen A; Tang C; McCarthy M; Francis R; Stricker P; Emmett L
BJU Int; 2022 Nov; 130 Suppl 3(Suppl 3):32-39. PubMed ID: 35488182
[TBL] [Abstract][Full Text] [Related]
17. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy.
Tendulkar RD; Agrawal S; Gao T; Efstathiou JA; Pisansky TM; Michalski JM; Koontz BF; Hamstra DA; Feng FY; Liauw SL; Abramowitz MC; Pollack A; Anscher MS; Moghanaki D; Den RB; Stephans KL; Zietman AL; Lee WR; Kattan MW; Stephenson AJ
J Clin Oncol; 2016 Oct; 34(30):3648-3654. PubMed ID: 27528718
[TBL] [Abstract][Full Text] [Related]
18. Development and Internal Validation of a Novel Nomogram Predicting the Outcome of Salvage Radiation Therapy for Biochemical Recurrence after Radical Prostatectomy in Patients without Metastases on Restaging Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography.
Meijer D; van Leeuwen PJ; Eppinga WSC; Vanneste BGL; Meijnen P; Daniels LA; van den Bergh RCN; Lont AP; Bodar YJL; Ettema RH; de Bie KCC; Oudshoorn FHK; Nieuwenhuijzen JA; van der Poel HG; Donswijk ML; Heymans MW; Oprea-Lager DE; Schaake EE; Vis AN
Eur Urol Open Sci; 2024 Mar; 61():37-43. PubMed ID: 38384437
[TBL] [Abstract][Full Text] [Related]
19. The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis.
Spohn SKB; Farolfi A; Schandeler S; Vogel MME; Ruf J; Mix M; Kirste S; Ceci F; Fanti S; Lanzafame H; Serani F; Gratzke C; Sigle A; Combs SE; Bernhardt D; Gschwend JE; Buchner JA; Trapp C; Belka C; Bartenstein P; Unterrainer L; Unterrainer M; Eiber M; Nekolla SG; Schiller K; Grosu AL; Schmidt-Hegemann NS; Zamboglou C; Peeken JC
Eur J Nucl Med Mol Imaging; 2022 Dec; 50(1):218-227. PubMed ID: 35984452
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN
Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]